Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Andreas Varkaris, Ph.D., M.D.

Title
Institution
Department
Address
Phone

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Sehgal K, Varkaris A, Viray H, VanderLaan PA, Rangachari D, Costa DB. Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized? J Immunother Cancer. 2020 06; 8(1). PMID: 32581048.
    Citations:    
  2. Arai S, Varkaris A, Nouri M, Chen S, Xie L, Balk SP. MARCH5 mediates NOXA-dependent MCL1 degradation driven by kinase inhibitors and integrated stress response activation. Elife. 2020 Jun 02; 9. PMID: 32484436.
    Citations:    
  3. Varkaris A, Xu W, Davis RB, Healy B, McDermott DF. Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2020 Jun; 18(3):179-184.e3. PMID: 32144046.
    Citations:    
  4. Varkaris A, Bubley G. Enzalutamide in Metastatic Prostate Cancer. N Engl J Med. 2019 10 10; 381(15):1493. PMID: 31597030.
    Citations:    
  5. Yang D, Thamcharoen N, Marcus C, Varkaris A, Aird W, Khankin EV, Cardarelli F. Unusual Presentation of Hemophagocytic Lymphohistiocytosis in a Kidney Transplant Patient. Case Rep Transplant. 2019; 2019:3682378. PMID: 30984439.
    Citations:    
  6. Varkaris A, Sehgal K, Rangachari D, Costa DB. Complete and Sustained Response of Brain Metastases to Programmed Death 1 Antibody Monotherapy in Treatment-naive Programmed Death Ligand 1-Positive Lung Cancer. J Thorac Oncol. 2019 02; 14(2):e34-e36. PMID: 30683297.
    Citations:    Fields:    
  7. Varkaris A, Katsiampoura A, Davis JS, Shah N, Lam M, Frias RL, Ivan C, Shimizu M, Morris J, Menter D, Overman M, Tran H, Heymach J, Chun YS, Vauthey JN, Calin G, Kopetz S. Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer. Br J Cancer. 2019 02; 120(3):340-345. PMID: 30636774.
    Citations:    Fields:    
  8. Katsiampoura A, Toumpanakis D, Konsta K, Varkaris A, Vassilakopoulos T. Prediction of dysnatremias in critically ill patients based on the law of conservation of mass. Comparison of existing formulae. PLoS One. 2018; 13(11):e0207603. PMID: 30475894.
    Citations:    Fields:    
  9. Varkaris A, Lewis DW, Nugent FW. Preserved Liver Transplant After PD-1 Pathway Inhibitor for Hepatocellular Carcinoma. Am J Gastroenterol. 2017 12; 112(12):1895-1896. PMID: 29215617.
    Citations: 1     Fields:    
  10. Katsiampoura A, Raghav K, Jiang ZQ, Menter DG, Varkaris A, Morelli MP, Manuel S, Wu J, Sorokin AV, Rizi BS, Bristow C, Tian F, Airhart S, Cheng M, Broom BM, Morris J, Overman MJ, Powis G, Kopetz S. Modeling of Patient-Derived Xenografts in Colorectal Cancer. Mol Cancer Ther. 2017 07; 16(7):1435-1442. PMID: 28468778.
    Citations: 1     Fields:    Translation:HumansAnimals
  11. Varkaris A, Gunturu K, Kewalramani T, Tretter C. Acute Myeloid Leukemia After Radium-223 Therapy: Case Report. Clin Genitourin Cancer. 2017 08; 15(4):e723-e726. PMID: 28024949.
    Citations: 1     Fields:    Translation:Humans
  12. Lee YC, Lin SC, Yu G, Cheng CJ, Liu B, Liu HC, Hawke DH, Parikh NU, Varkaris A, Corn P, Logothetis C, Satcher RL, Yu-Lee LY, Gallick GE, Lin SH. Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer. Cancer Res. 2015 Nov 15; 75(22):4949-59. PMID: 26530902.
    Citations: 7     Fields:    Translation:HumansAnimalsCells
  13. Gaur S, Wen Y, Song JH, Parikh NU, Mangala LS, Blessing AM, Ivan C, Wu SY, Varkaris A, Shi Y, Lopez-Berestein G, Frigo DE, Sood AK, Gallick GE. Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. Oncotarget. 2015 Oct 06; 6(30):29161-77. PMID: 26313360.
    Citations: 12     Fields:    Translation:HumansAnimalsCells
  14. Varkaris A, Corn PG, Parikh NU, Efstathiou E, Song JH, Lee YC, Aparicio A, Hoang AG, Gaur S, Thorpe L, Maity SN, Bar Eli M, Czerniak BA, Shao Y, Alauddin M, Lin SH, Logothetis CJ, Gallick GE. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer. Clin Cancer Res. 2016 Jan 01; 22(1):107-21. PMID: 26272062.
    Citations: 10     Fields:    Translation:HumansAnimalsCells
  15. Chatterji T, Varkaris AS, Parikh NU, Song JH, Cheng CJ, Schweppe RE, Alexander S, Davis JW, Troncoso P, Friedl P, Kuang J, Lin SH, Gallick GE. Yes-mediated phosphorylation of focal adhesion kinase at tyrosine 861 increases metastatic potential of prostate cancer cells. Oncotarget. 2015 Apr 30; 6(12):10175-94. PMID: 25868388.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  16. Varkaris A, Katsiampoura AD, Araujo JC, Gallick GE, Corn PG. Src signaling pathways in prostate cancer. Cancer Metastasis Rev. 2014 Sep; 33(2-3):595-606. PMID: 24522479.
    Citations: 17     Fields:    Translation:HumansAnimalsCells
  17. Varkaris A, Gaur S, Parikh NU, Song JH, Dayyani F, Jin JK, Logothetis CJ, Gallick GE. Ligand-independent activation of MET through IGF-1/IGF-1R signaling. Int J Cancer. 2013 Oct 01; 133(7):1536-46. PMID: 23526299.
    Citations: 17     Fields:    Translation:HumansAnimalsCells
  18. Dayyani F, Varkaris A, Araujo JC, Song JH, Chatterji T, Trudel GC, Logothetis CJ, Gallick GE. Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancer. Prostate. 2013 Jun; 73(9):979-85. PMID: 23371521.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  19. Dayyani F, Parikh NU, Varkaris AS, Song JH, Moorthy S, Chatterji T, Maity SN, Wolfe AR, Carboni JM, Gottardis MM, Logothetis CJ, Gallick GE. Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways. PLoS One. 2012; 7(12):e51189. PMID: 23300537.
    Citations: 13     Fields:    Translation:HumansAnimalsCells
  20. Varkaris A, Corn PG, Gaur S, Dayyani F, Logothetis CJ, Gallick GE. The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin Investig Drugs. 2011 Dec; 20(12):1677-84. PMID: 22035268.
    Citations: 26     Fields:    Translation:Humans
  21. Bournakis E, Efstathiou E, Varkaris A, Wen S, Chrisofos M, Deliveliotis C, Alamanis C, Anastasiou I, Constantinides C, Bamias A, Dimopoulos MA. Time to castration resistance is an independent predictor of castration-resistant prostate cancer survival. Anticancer Res. 2011 Apr; 31(4):1475-82. PMID: 21508406.
    Citations: 2     Fields:    Translation:Humans
  22. Mountzios I, Bournakis E, Efstathiou E, Varkaris A, Wen S, Chrisofos M, Deliveliotis C, Alamanis C, Anastasiou I, Constantinides C, Karadimou A, Tsiatas M, Papadimitriou C, Bamias A, Dimopoulos MA. Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer. Urology. 2011 Mar; 77(3):682-7. PMID: 21256546.
    Citations: 5     Fields:    Translation:Humans
  23. Kastritis E, Charidimou A, Varkaris A, Dimopoulos MA. Targeted therapies in multiple myeloma. Target Oncol. 2009 Jan; 4(1):23-36. PMID: 19343299.
    Citations: 6     Fields:    Translation:HumansAnimalsCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Varkaris's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (137)
Explore
_
Co-Authors (15)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.